mereo biopharma 1 limited Company Information
Company Number
09646998
Next Accounts
Sep 2025
Industry
Research and experimental development on biotechnology
Shareholders
mereo biopharma group plc
Group Structure
View All
Contact
Registered Address
4th floor, one cavendish place, london, W1G 0QF
Website
www.mereobiopharma.commereo biopharma 1 limited Estimated Valuation
Pomanda estimates the enterprise value of MEREO BIOPHARMA 1 LIMITED at £0 based on a Turnover of £0 and 1.5x industry multiple (adjusted for size and gross margin).
mereo biopharma 1 limited Estimated Valuation
Pomanda estimates the enterprise value of MEREO BIOPHARMA 1 LIMITED at £0 based on an EBITDA of £-343.8k and a 5.36x industry multiple (adjusted for size and gross margin).
mereo biopharma 1 limited Estimated Valuation
Pomanda estimates the enterprise value of MEREO BIOPHARMA 1 LIMITED at £7.9m based on Net Assets of £4.3m and 1.84x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Mereo Biopharma 1 Limited Overview
Mereo Biopharma 1 Limited is a live company located in london, W1G 0QF with a Companies House number of 09646998. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in June 2015, it's largest shareholder is mereo biopharma group plc with a 100% stake. Mereo Biopharma 1 Limited is a established, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Mereo Biopharma 1 Limited Health Check
There is insufficient data available to calculate a health check for Mereo Biopharma 1 Limited. Company Health Check FAQs
0 Strong
0 Regular
0 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Mereo Biopharma 1 Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Mereo Biopharma 1 Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- Mereo Biopharma 1 Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- Mereo Biopharma 1 Limited
- - Industry AVG
Employees
There is insufficient data available for this Key Performance Indicator!
- - Mereo Biopharma 1 Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Mereo Biopharma 1 Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Mereo Biopharma 1 Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Mereo Biopharma 1 Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Mereo Biopharma 1 Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Mereo Biopharma 1 Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Mereo Biopharma 1 Limited
- - Industry AVG
Debt Level
There is insufficient data available for this Key Performance Indicator!
- - Mereo Biopharma 1 Limited
- - Industry AVG
MEREO BIOPHARMA 1 LIMITED financials
Mereo Biopharma 1 Limited's latest turnover from December 2023 is estimated at 0 and the company has net assets of £4.3 million. According to their latest financial statements, we estimate that Mereo Biopharma 1 Limited has no employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | |
---|---|---|---|---|---|---|---|---|---|
Turnover | |||||||||
Other Income Or Grants | |||||||||
Cost Of Sales | |||||||||
Gross Profit | |||||||||
Admin Expenses | |||||||||
Operating Profit | |||||||||
Interest Payable | |||||||||
Interest Receivable | |||||||||
Pre-Tax Profit | |||||||||
Tax | |||||||||
Profit After Tax | |||||||||
Dividends Paid | |||||||||
Retained Profit | |||||||||
Employee Costs | |||||||||
Number Of Employees | |||||||||
EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | |
---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 4,310,761 | 4,310,761 | 4,310,761 | 4,310,761 | 4,310,761 | 4,310,761 | 4,310,761 | 4,310,761 | 4,310,761 |
Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 152,400 | 0 | 0 |
Total Fixed Assets | 4,310,761 | 4,310,761 | 4,310,761 | 4,310,761 | 4,310,761 | 4,310,761 | 4,463,161 | 4,310,761 | 4,310,761 |
Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group Debtors | 0 | 0 | 0 | 197,765 | 0 | 0 | 0 | 0 | 1 |
Misc Debtors | 0 | 0 | 0 | 26,564 | 648,462 | 0 | 0 | 0 | 0 |
Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 525,552 | 2,170,254 | 2,102,469 | 300,024 |
total current assets | 0 | 0 | 0 | 224,329 | 648,462 | 525,552 | 2,170,254 | 2,102,469 | 300,025 |
total assets | 4,310,761 | 4,310,761 | 4,310,761 | 4,535,090 | 4,959,223 | 4,836,313 | 6,633,415 | 6,413,230 | 4,610,786 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 4,811,123 | 0 | 0 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 4,811,123 | 0 | 0 |
loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8,211,558 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 51,954 | 0 | 135,082 | 0 | 0 |
other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 0 | 0 | 0 | 0 | 51,954 | 93,518 | 135,082 | 0 | 8,211,558 |
total liabilities | 0 | 0 | 0 | 0 | 51,954 | 93,518 | 4,946,205 | 0 | 8,211,558 |
net assets | 4,310,761 | 4,310,761 | 4,310,761 | 4,535,090 | 4,907,269 | 4,742,795 | 1,687,210 | 6,413,230 | -3,600,772 |
total shareholders funds | 4,310,761 | 4,310,761 | 4,310,761 | 4,535,090 | 4,907,269 | 4,742,795 | 1,687,210 | 6,413,230 | -3,600,772 |
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | |
---|---|---|---|---|---|---|---|---|---|
Operating Activities | |||||||||
Operating Profit | |||||||||
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Tax | |||||||||
Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors | 0 | 0 | -224,329 | -424,133 | 648,462 | -152,400 | 152,400 | -1 | 1 |
Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | -51,954 | 51,954 | -135,082 | 135,082 | 0 | 0 |
Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | |||||||||
Investing Activities | |||||||||
capital expenditure | |||||||||
Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
cash flow from investments | |||||||||
Financing Activities | |||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | -4,811,123 | 4,811,123 | 0 | 0 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8,211,558 | 8,211,558 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
share issue | |||||||||
interest | |||||||||
cash flow from financing | |||||||||
cash and cash equivalents | |||||||||
cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
change in cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
mereo biopharma 1 limited Credit Report and Business Information
Mereo Biopharma 1 Limited Competitor Analysis
Perform a competitor analysis for mereo biopharma 1 limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other established companies, companies in W1G area or any other competitors across 12 key performance metrics.
mereo biopharma 1 limited Ownership
MEREO BIOPHARMA 1 LIMITED group structure
Mereo Biopharma 1 Limited has no subsidiary companies.
mereo biopharma 1 limited directors
Mereo Biopharma 1 Limited currently has 3 directors. The longest serving directors include Dr Denise Scots-Knight (Jun 2015) and Mr Charles Sermon (Jun 2015).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Dr Denise Scots-Knight | England | 65 years | Jun 2015 | - | Director |
Mr Charles Sermon | England | 55 years | Jun 2015 | - | Director |
Ms Christine Fox | United Kingdom | 44 years | Jan 2021 | - | Director |
P&L
December 2023turnover
0
0%
operating profit
-343.8k
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
4.3m
0%
total assets
4.3m
0%
cash
0
0%
net assets
Total assets minus all liabilities
mereo biopharma 1 limited company details
company number
09646998
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
June 2015
age
10
incorporated
UK
ultimate parent company
accounts
Small Company
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
-
address
4th floor, one cavendish place, london, W1G 0QF
Bank
-
Legal Advisor
-
mereo biopharma 1 limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to mereo biopharma 1 limited. Currently there are 0 open charges and 2 have been satisfied in the past.
mereo biopharma 1 limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for MEREO BIOPHARMA 1 LIMITED. This can take several minutes, an email will notify you when this has completed.
mereo biopharma 1 limited Companies House Filings - See Documents
date | description | view/download |
---|